USA-based Health Discovery Corp has licensed its new molecular diagnostics gene-based tests for clinically-significant prostate cancer to health care major Abbott Laboratories.
The latter has acquired co-exclusive clinical laboratory rights and exclusive in vitro diagnostic rights for commercialization of HDC's tissue-based prostate cancer test as well as its urine-based prostate cancer test.
Through the application of its patent protected technology, HDC develops SVM-based molecular diagnostic and prognostic test development in genomics and proteomics, as well as digital image analysis in pathology and radiology.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze